Home › Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I
 

Keywords :   


Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I

2014-12-29 01:43:03| drugdiscoveryonline Home Page

PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I)

Tags: of i europe treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.09Washington Corner | September 2024
27.09Hurricane Isaac Graphics
27.09Remnants of John Graphics
27.09Remnants of John Forecast Discussion Number 20
27.09Remnants of John Wind Speed Probabilities Number 20
27.09Remnants of John Public Advisory Number 20
27.09Summary for Remnants of John (EP5/EP102024)
27.09Tropical Storm Joyce Graphics
More »